ETF DAILY NEWS

Atyr PHARMA (NASDAQ:ATYR) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR – Free Report) in a research note published on Friday morning,Benzinga reports. They currently have a $35.00 price objective on the stock. A number of other research firms have also issued reports on ATYR. Leerink Partners began coverage on Atyr PHARMA in a […]

Mar 17, 2025 - 07:15
 0
Atyr PHARMA (NASDAQ:ATYR) Earns “Buy” Rating from HC Wainwright
HC Wainwright reissued their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR – Free Report) in a research note published on Friday morning,Benzinga reports. They currently have a $35.00 price objective on the stock. A number of other research firms have also issued reports on ATYR. Leerink Partners began coverage on Atyr PHARMA in a […]
Read More

Tags:

Previous Article

Lyra Therapeutics (NASDAQ:LYRA) Given Neutral Rating at HC Wainwright

Next Article

ARMOUR Residential REIT (NYSE:ARR) and Empire State Realty Trust (NYSE:ESRT) Fin...

Related Posts

Norwegian Air Shuttle ASA (NWARF) to Release Earnings on Thursday

Norwegian Air Shuttle ASA (NWARF) to Release Earnings o...

Feb 11, 2025  0

Rhumbline Advisers Lowers Holdings in HF Sinclair Co. (NYSE:DINO)

Rhumbline Advisers Lowers Holdings in HF Sinclair Co. (...

Feb 22, 2025  0

Weyerhaeuser (NYSE:WY) Receives $35.00 Consensus Target Price from Analysts

Weyerhaeuser (NYSE:WY) Receives $35.00 Consensus Target...

Mar 3, 2025  0